Yacine Salhi

2.4k total citations · 1 hit paper
32 papers, 1.7k citations indexed

About

Yacine Salhi is a scholar working on Oncology, Surgery and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Yacine Salhi has authored 32 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 9 papers in Surgery and 7 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Yacine Salhi's work include Bladder and Urothelial Cancer Treatments (8 papers), Urinary and Genital Oncology Studies (8 papers) and Monoclonal and Polyclonal Antibodies Research (7 papers). Yacine Salhi is often cited by papers focused on Bladder and Urothelial Cancer Treatments (8 papers), Urinary and Genital Oncology Studies (8 papers) and Monoclonal and Polyclonal Antibodies Research (7 papers). Yacine Salhi collaborates with scholars based in United States, France and Germany. Yacine Salhi's co-authors include Joaquim Bellmunt, Hans von der Maase, Stéphane Culine, Eric Winquist, Ronan Fougeray, Toni K. Choueiri, Jacob Rosenberg, Agnieszka Jagiełło-Gruszfeld, Nassim Morsli and Armelle Caty and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Yacine Salhi

32 papers receiving 1.7k citations

Hit Papers

Phase III Trial of Vinflunine Plus Best Supportive Care C... 2009 2026 2014 2020 2009 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Phase III Trial of Vinflunine Plus Best Supportive Care Compared With Best Supportive Care Alone After a Platinum-Containing Regimen in Patients With Advanced Transitional Cell Carcinoma of the Urothelial Tract
    2009 543 citations Joaquim Bellmunt, Yacine Salhi et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Yacine Salhi United States 15 936 769 485 181 168 32 1.7k
M. Gapany United States 22 657 0.7× 698 0.9× 370 0.8× 80 0.4× 33 0.2× 265 1.9k
Kim Ely United States 20 476 0.5× 585 0.8× 447 0.9× 144 0.8× 88 0.5× 51 2.0k
Yutaka Ogata Japan 20 509 0.5× 832 1.1× 434 0.9× 40 0.2× 104 0.6× 98 1.6k
Lucio Manenti Italy 18 323 0.3× 129 0.2× 314 0.6× 131 0.7× 55 0.3× 44 1.1k
Fredrik Enlund Sweden 18 444 0.5× 555 0.7× 231 0.5× 341 1.9× 14 0.1× 31 1.4k
Hariklia Gakiopoulou Greece 20 454 0.5× 512 0.7× 156 0.3× 32 0.2× 57 0.3× 54 1.4k
Tao Ji United States 10 833 0.9× 637 0.8× 400 0.8× 66 0.4× 12 0.1× 28 1.5k
Shinsuke Kazama Japan 26 731 0.8× 1.4k 1.8× 450 0.9× 24 0.1× 44 0.3× 109 2.2k
Jin Sik Min South Korea 24 922 1.0× 874 1.1× 855 1.8× 26 0.1× 48 0.3× 70 1.9k
Lara Alessandrini Italy 17 237 0.3× 284 0.4× 199 0.4× 20 0.1× 72 0.4× 69 827

Countries citing papers authored by Yacine Salhi

Since Specialization
Citations

This map shows the geographic impact of Yacine Salhi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yacine Salhi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yacine Salhi more than expected).

Fields of papers citing papers by Yacine Salhi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yacine Salhi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yacine Salhi. The network helps show where Yacine Salhi may publish in the future.

Co-authorship network of co-authors of Yacine Salhi

This figure shows the co-authorship network connecting the top 25 collaborators of Yacine Salhi. A scholar is included among the top collaborators of Yacine Salhi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yacine Salhi. Yacine Salhi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Bossard, Céline, Yacine Salhi, Jérôme Chetritt, & Saı̈d Salhi. (2024). 1121P Artificial Intelligence to predict BRAF mutational status from whole slide images in melanoma. Annals of Oncology. 35. S739–S739. 1 indexed citations
2.
Sia, Hanlon, Joshua Richter, Tara Cochrane, et al.. (2022). A Phase 1/2, First-in-Human, Multicenter, Open-Label, Dose Escalation and Dose-Expansion Study of Single-Agent ISB 1442 in Patients with Relapsed/Refractory Multiple Myeloma. Blood. 140(Supplement 1). 10182–10184. 3 indexed citations
3.
Gudi, Girish, et al.. (2021). 472 Telazorlimab in atopic dermatitis: Phase 2b study shows improvement at 16 weeks. Journal of Investigative Dermatology. 141(5). S82–S82. 4 indexed citations
4.
Guttman‐Yassky, Emma, Janet Lee, Ana B. Pavel, Yacine Salhi, & G. Wolff. (2019). Evidence for Activity of GBR830 (Anti-OX40) in Extrinsic and Intrinsic Atopic Dermatitis (AD) in a Phase 2a Study. Journal of Allergy and Clinical Immunology. 143(2). AB127–AB127. 1 indexed citations
5.
Andrews, Charles P., et al.. (2019). Efficacy and safety of twice-daily and once-daily olopatadine-mometasone combination nasal spray for seasonal allergic rhinitis. Annals of Allergy Asthma & Immunology. 124(2). 171–178.e2. 29 indexed citations
6.
Guttman‐Yassky, Emma, Ana B. Pavel, Lisa Zhou, et al.. (2019). GBR 830, an anti-OX40, improves skin gene signatures and clinical scores in patients with atopic dermatitis. Journal of Allergy and Clinical Immunology. 144(2). 482–493.e7. 160 indexed citations
7.
Richter, Joshua, Ola Landgren, John Kauh, et al.. (2018). Phase 1, multicenter, open-label study of single-agent bispecific antibody t-cell engager GBR 1342 in relapsed/refractory multiple myeloma.. Journal of Clinical Oncology. 36(15_suppl). TPS3132–TPS3132. 19 indexed citations
8.
Wermke, Martin, John Kauh, Jonathan Back, et al.. (2018). Preliminary biomarker and pharmacodynamic data from a phase I study of single-agent bispecific antibody T-cell engager GBR 1302 in subjects with HER2-positive cancers.. Journal of Clinical Oncology. 36(5_suppl). 69–69. 9 indexed citations
9.
Gudi, Girish, et al.. (2018). 1094 Clinical pharmacokinetics and immunogenicity of GBR 830, a first-in-class humanized monoclonal antibody inhibiting OX40 to treat atopic dermatitis. Journal of Investigative Dermatology. 138(5). S185–S185. 3 indexed citations
10.
Richter, Joshua, Martin Wermke, John Kauh, et al.. (2018). Phase 1, multicenter, open-label study of single-agent bispecific antibody T-cell engager GBR 1342 in relapsed/refractory multiple myeloma.. Journal of Clinical Oncology. 36(5_suppl). TPS81–TPS81. 15 indexed citations
11.
Guttman‐Yassky, Emma, Ana B. Pavel, Yeriel Estrada, et al.. (2018). 453 GBR 830 induces progressive and sustained changes in atopic dermatitis biomarkers in patient skin lesions. Journal of Investigative Dermatology. 138(5). S77–S77. 4 indexed citations
12.
Wermke, Martin, et al.. (2016). A phase 1 study of GBR 1302 in subjects with HER2-positive cancers. Annals of Oncology. 27. viii16–viii16. 2 indexed citations
13.
14.
Pond, Gregory R., Joaquim Bellmunt, Ronan Fougeray, et al.. (2013). Impact of Response to Prior Chemotherapy in Patients With Advanced Urothelial Carcinoma Receiving Second-Line Therapy: Implications for Trial Design. Clinical Genitourinary Cancer. 11(4). 495–500. 20 indexed citations
15.
Harshman, Lauren C., Ronan Fougeray, Toni K. Choueiri, et al.. (2013). The impact of prior platinum therapy on survival in patients with metastatic urothelial cancer receiving vinflunine. British Journal of Cancer. 109(10). 2548–2553. 11 indexed citations
16.
Krajewski, Katherine M., Ronan Fougeray, Joaquim Bellmunt, et al.. (2011). Optimisation of the size variation threshold for imaging evaluation of response in patients with platinum-refractory advanced transitional cell carcinoma of the urothelium treated with vinflunine. European Journal of Cancer. 48(10). 1495–1502. 17 indexed citations
17.
Salhi, Yacine, et al.. (2010). Xeroderma pigmentosum compliqué d’une tumeur intracérébrale : à propos d’un cas. Journal Français d Ophtalmologie. 33(7). 495.e1–495.e4. 2 indexed citations
18.
Yovine, Alejandro, M. Riofrio, Jean‐Yves Blay, et al.. (2004). Phase II Study of Ecteinascidin-743 in Advanced Pretreated Soft Tissue Sarcoma Patients. Journal of Clinical Oncology. 22(5). 890–899. 261 indexed citations
19.
Lallemand, Francis, Nathalie Adda, Véronique Schneider, et al.. (1999). Prospective Follow‐Up of 67 Indinavir‐Experienced Human Immunodeficiency Virus‐Infected and AIDS Patients Treated with the Ritonavir/Saquinavir Combination. Clinical Infectious Diseases. 28(5). 1184–1185. 4 indexed citations
20.
Salhi, Yacine, Dominique Costagliola, Paolo Rebulla, et al.. (1998). Serum Ferritin, Desferrioxamine, and Evolution of HIV-1 Infection in Thalassemic Patients. Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology. 18(5). 473–478. 54 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by M. Gapany Breakdown of academic impact, for papers by Kim Ely Breakdown of academic impact, for papers by Yutaka Ogata Breakdown of academic impact, for papers by Lucio Manenti Breakdown of academic impact, for papers by Fredrik Enlund Breakdown of academic impact, for papers by Hariklia Gakiopoulou Breakdown of academic impact, for papers by Tao Ji Breakdown of academic impact, for papers by Shinsuke Kazama Breakdown of academic impact, for papers by Jin Sik Min Breakdown of academic impact, for papers by Lara Alessandrini
Rankless by CCL
2026